Amivantamab as a salvage therapy post-EGFR-tyrosine kinase inhibitor failure in patients with mutated EGFR non-small cell lung cancer

Bilal Krayim, Waleed Kian, Maria Spector, Inbal Granot, Julia Dudnik, Michal Nissim, Dolev Kahala, Areen Abu Remilah, Naama R. Bogot, Gleb Kornev, Noam Asna, Nir Peled, Laila C. Roisman